Drug, bio-affecting and body treating compositions inventions 10/08

20080260635 - Cytotoxicity mediation of cells evidencing surface expression of mcsp: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The... Agent: Mchale & Slavin, P.A.

20080260634 - Diagnostic use of endothelin etb receptor agonists and eta receptor antagonists in tumor imaging: Methods of imaging tumors are disclosed. The methods utilize an endothelin ETB receptor agonist or an endothelin ETA receptor antagonist, in combination with an imaging agent, to detect a tumor in mammals, including humans.... Agent: Marshall, Gerstein & Borun LLP

20080260636 - Stabilization of radionuclide-containing compositions: Described are methods for stabilizing radionuclide-containing compositions against degradation caused by free radicals generated from the radionuclide. Iodide ions stabilize the radionuclide-containing compositions by acting as scavengers to generated free radicals, thus, preventing or lessening degradation therefrom. Among the preferred radionuclide-containing compositions to be stabilized are complexes of a complexing... Agent: Millen, White, Zelano & Branigan, P.C.

20080260637 - Methods of detecting prostate cancer: A method of detecting presence or absence of prostate cancer in a subject, both in vivo and ex vivo is disclosed. The method comprises analyzing mitochondria or a mitochondrial component in at least one prostate cell of the subject, whereby mitochondria an alteration in quantity and or characteristic is indicative... Agent: Martin D. Moynihan Prtsi

20080260639 - Preparation and method utilizing radiolabeled chlorotoxin: The inventors propose to label a chlorotoxin with I-123 or I-124 for a diagnostic agent, and with I-124 or I-131 for a therapeutic agent to reduce tumors and then to use a process they previously invented to stabilize the radiopharmaceutical. The inventors propose to reconstitute the preferred agents and administer... Agent: Brooke Schumm Iii Daneker, Mcintire, Schumm, Prince, Goldstein Et Al

20080260638 - Receptor(sstr2)-selective somatostatin antagonists: SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4... Agent: Fitch Even Tabin And Flannery

20080260642 - Bacteriophage-based contrast agents, the use thereof and a method for the production thereof: Bacteriophage-based contrast agents and a method for the production thereof are disclosed. The bacteriophages, in at least one embodiment, contain a first fusion protein comprising a phage-surface protein and a ligand specific for an identifiable target structure and a second fusion protein comprising a phage-surface protein and a peptide binding... Agent: Harness, Dickey & Pierce, P.L.C

20080260641 - Human monoclonal antibodies against cd20: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080260640 - Use of precursors of tachykinins and/or their fragments in medical diagnostic: The present invention relates to the use of protachykinin and/or fragments thereof that can be isolated from body fluids, tissues or other biological samples and therefore, serves as a marker peptide for medical diagnosis of diseases/disorders of the central nervous system, including Alzheimer's disease, Parkinson's disease, depression and/or conditions of... Agent: Heslin Rothenberg Farley & Mesiti PC

20080260644 - Chloride transport upregulation for the treatment of traumatic brain injury: Compositions and methods are provided for the alleviation of pathology induced by traumatic brain injury.... Agent: Dann, Dorfman, Herrell & Skillman

20080260645 - Method and use of cold-pressed botanic seed oils for lowering blood pressure and ldl cholesterol: m

20080260643 - Use of pde7 inhibitors for the treatment of movement disorders: A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20080260646 - Imaging reporters of transgene expression: Disclosed are compositions and methods for imaging in animals.... Agent: Morgan, Lewis & Bockius LLP (sf)

20080260648 - Pharmaceutical preparation containing magnetic vesicular particles, manufacturing method thereof and diagnostic therapeutic system: s

20080260649 - Method of dynamic nuclear polarisation dnp: The invention relates to a method of dynamic nuclear polarisation (DNP) using a combination of a trityl radical and a paramagnetic metal ion as the polarising agent leading to enhanced levels of polarisation in the sample to be polarised and to compositions and polarising agents for use in the method.... Agent: Ge Healthcare, Inc.

20080260650 - Methods of detection and therapy of inflamed tissues using immune modulation: The present invention relates to methods for the detection and therapy of inflamed tissue, whereby immune modulators are used to increase the uptake of diagnostic or therapeutic compositions by inflammatory cells.... Agent: Ewards Angell Palmer & Dodge LLP

20080260651 - Contrast agents: e

20080260647 - Method for fluorescence tomographic imaging: There is provided a method for determining the concentration of a fluorophore in a medium using moments of order k of the fluorescence signal. The method allows higher fidelity 3-dimensional reconstructions of the fluorophore in the medium. The method can be applied in imaging of fluorophores in biological tissues.... Agent: Bereskin And Parr

20080260652 - Composition for dyeing dental plaque for evaluating dental caries activity: An objective of the present invention is to provide a composition for dyeing dental plaque for evaluation of dental caries activity that is capable of simultaneously dyeing dental plaque and evaluating dental caries activity, and which can evaluate thick dental plaque more accurately than the conventional technique. The composition for... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260655 - Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses: The present invention relates to stable substantially non-aqueous, non-alcoholic, non-silicone, foamable carrier compositions comprising petrolatum or mixtures thereof, at least one foam agent, at least one propellant, and with and without the addition of an active agent. The formulations may contain a solvent substantially miscible therein. The present invention further... Agent: Wilmerhale/boston

20080260654 - Sustained release composition of protein drug: Disclosed is a sustained release composition of a protein drug. The composition comprises a carrier substrate and a protein drug incorporated in the carrier substrate. The carrier substrate is consisting essentially of a hyaluronic acid or its salts, an amino acid, and a polyalkyl oxide.... Agent: Cantor Colburn, LLP

20080260653 - Transdermal delivery systems and transdermal chelation preparations: The invention provides topical chelating preparations and formulations. The invention provides methods of transepithelial delivery of a topical chelating preparation to a human or other animal by topical application to the skin of a human or animal of a topical chelating preparation. In one aspect, a preparation or formulation of... Agent: Morrison & Foerster LLP

20080260656 - Ungual/periungual compositions comprising morpholine compounds and water-soluble film-forming agents: Pharmaceutical compositions suited for ungual and periungual application and useful for the treatment of dermatological conditions/afflictions, in particular onychomycosis, contain an anti-mycotic agent of the family of the morpholines and a water-soluble film-forming agent.... Agent: Buchanan, Ingersoll & Rooney PC

20080260657 - Process for milling poorly soluble drugs in presence of liquid propellants: Drug substance for use in a pharmaceutical formulation may be prepared by a process which process comprises co-milling a suspension of the drug substance and a pharmaceutically acceptable polymer in a liquid propellant.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080260659 - Compositions: The invention is directed to personal care products and compositions that comprise at least one preservative compound selected from the group consisting of benzoic acid, p-hydroxy-benzoic acid, methyl-paraben, ethyl-paraben, propyl-paraben, isopropyl-paraben, butyl-paraben, isobutyl-paraben, benzyl-paraben, or a salt thereof, in a total concentration of 0.1% to 0.5% (w/w); and at least... Agent: Norris, Mclaughlin & Marcus

20080260658 - Hair setting compositions based on t-butyl acrylate and hydroxyalkyl methacrylate: The present invention relates to copolymers, which comprises, in copolymerized form, between 25 and 80% by weight of tert-butyl (meth)acrylate, 2 to 60% by weight of hydroxyalkyl (meth)acrylate, 10 to 40% by weight of an anionic or anionogenic, free-radically polymerizable, olefinically unsaturated compound which is or comprises methacrylic acid, and,... Agent: Connolly Bove Lodge & Hutz, LLP

20080260660 - Teeth whitening agents: The invention relates to light-activated teeth whitening compositions, and to the use thereof for lightening teeth. The inventive whitening agent contains riboflavin and or the derivatives thereof, which enable the oxidant in the whitening agent to decompose more rapidly, by means of radiation energy, thus effectively accelerating the whitening action.... Agent: Edwards Angell Palmer & Dodge LLP

20080260661 - Aminobutadiene-based uv screens: The invention relates to the use of an UV-absorbing compound for the preparation of a cosmetic composition for protection against UV radiation said compound being represented by the general formula (I) wherein less than 10% of the total absorption between 250 and 600 nm of said UV-absorbing compound according to... Agent: Foley And Lardner LLP Suite 500

20080260663 - Esterification reaction products and cosmetic products: e

20080260662 - Sunscreen compositions comprising carotenoids: The invention concerns methods of treating or preventing the effects of irradiation in a human or non-human animal using carotenoid compounds, preferably diadinoxanthin, diatoxanthin and/or fucoxanthin as well as photoprotective compositions and their use to prepare photoprotective or photoprotected products.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080260664 - Particles functionalized with organic compounds: The present invention relates to particles comprising an inorganic network and organic compounds covalently bonded to the network via a spacer group, where the organic compounds are present in the interior of the particles and optionally also on the surface of the particles. The present invention furthermore relates to processes... Agent: Millen, White, Zelano & Branigan, P.C.

20080260665 - Nail varnish comprising at least one polycondensate and at least one polyoxyalkylene copolymer: copolymers comprising at least one polyethylene glycol block and at least one polypropylene glycol block, the said copolymer exhibiting a molecular weight of greater than or equal to 1000 g/mol and their mixtures.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080260666 - Cosmetic compositions comprising at least one non-ionic surfactant and at least one vinylamide/vinylamine copolymer and methods of use thereof: p

20080260667 - Use of halogenated hydroxydiphenyl ether compounds for the treatment of the skin:

20080260668 - Method for preparing a compound for drawing a non-permanent tattoo and a method of using said compound: The present invention refers to a method for preparing of a compound for drawing a non-permanent tattoo from the “jenipapo” fruit (Genipa americana). A certain amount of juice from the “jenipapo” fruit (Genipa americana) is provided, into which a thickener is added for forming a substantially creamy compound, which receives... Agent: Ronald R Santucci Frommer Lawrence Haug LLP

20080260669 - Aromachemicals: wherein R1 and R2 represent, independently, linear or branched C1-4 alkyl, n=0 to 4 and m=0 to 3. Mixtures of these compounds, methods for their preparation, their use as perfume materials for application to a variety of substrates and their use in flavouring and in articles of manufacture is also... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080260670 - Organic compounds: e

20080260672 - Aqueous preservative solution with high amino acid content: Aqueous preservative solutions with a high amino acid content which is excellent in preservation, particularly a preservative effect on fungi, and safety, and is excellent in storage stability so as not to cause a problem such as depositing, coloring or smelling even when it is stored for a long time,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260671 - Depilatory compositions: A depilatory composition comprising a depilatory compound having a thiol group and a quinone and/or phenol compound.... Agent: Merchant & Gould PC

20080260674 - Cosmetic use of amphoteric polysaccharide compounds containing cationic polymer chain (s): The invention relates to the cosmetic use, especially for the cosmetic treatment of keratin materials, of amphoteric polysaccharide compounds containing cationic polymer chain(s), which may be obtained by grafting and polymerization of ethylenic monomers of formula (I), Q− onto an anionic polysaccharide of formula (II): in the presence of a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080260675 - Depolymerized scleroglucan for regulating and improving the moisture content of the skin: The use of depolymerized scleroglucan alone, or in combination with one or more active ingredients as a moisturizer, and as anti-inflammatory active ingredient for protecting and for restoring a healthy skin barrier in the field of cosmetic or dermatological skincare is disclosed.... Agent: Scully Scott Murphy & Presser, PC

20080260673 - Conditioning composition: The present invention is related to composition for conditioning keratin fibres especially human hair with reduced bulk density. The inventors of the present invention have found out that a conditioning composition comprising at least one shear thickening polymer and at least one conditioning compound and having reduced bulk density solves... Agent: Norris, Mclaughlin & Marcus, P.A.

20080260676 - Hydroxycucurbituril derivatives, their preparation methods and uses: Provided are hydroxycucurbituril derivatives, their preparation methods and uses. The hydroxycucurbituril derivative is easy to further functionalize with enhanced solubility in common solvents, thereby providing wider applications.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080260677 - Transdermal topical composition and its uses: An emollient component is provided in a composition, suitable for topical application to skin, comprising a fugitive solvent base comprising at least one alcohol. One advantage of the invention is that the irritancy potential of the composition due to the alcoholic fugitive solvent base is reduced.... Agent: Catalyst Law Group, Apc

20080260679 - Methods and compositions for treatment of ion imbalances: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment... Agent: Senniger Powers LLP

20080260678 - Molecular band-aid: A molecular sealant comprising a therapeutically effective amount of a poloxamer capable of sealing a cell or tissue from leaks. A method of treating tissue leakages by applying the above sealant to the tissue or cell in need of treatment. A composition for treating cellular leakages comprising a poloxamer capable... Agent: Warner Norcross & Judd LLP

20080260680 - Method of attenuating reactions to skin irritants: The present invention is directed to a method of inhibiting CDld activation by administering a composition containing a moiety that blocks CDld activation. Compositions of the invention are useful for the attenuation of CDld-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for... Agent: Wilson Sonsini Goodrich & Rosati

20080260681 - Compositions and methods for treating and preventing cardiomyopathy and heart disease: The present invention relates to compositions and methods for treating and preventing heart disease. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188-P1 88) and methods of using the same for treating and preventing heart disease (e.g., in subjects with muscular dystrophy) and for treating cells and... Agent: Tyler J. Sisk Casimir Jones

20080260682 - Polyethylene glycol colonic purgative composition: This invention relates to novel colonic purgative compositions of polyethylene glycol having an average molecular weight of at least 1,000 or at least 4,000. Further, this invention relates to methods of using the colonic purgative compositions. The formulations and methods of this invention are particularly useful to cleanse the bowel... Agent: Edwards Angell Palmer & Dodge LLP

20080260683 - Rodenticide: The invention relates to the systemic insecticide fipronil in conjunction with a rodenticide used for manufacture of a bait composition to provide a lethal effect on fleas and/or ticks and a host rodent, following ingestion of the bait composition by the host rodent. Preferred rodenticides are brodifacoum, difethialone, flocoumafen, bromadiolone... Agent: Fish & Richardson PC

20080260684 - Method for the purification of g-csf: The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying... Agent: Knobbe Martens Olson & Bear LLP

20080260685 - Prodrugs of cc-1065 analogs: Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a... Agent: Sughrue Mion, PLLC

20080260686 - Methods of using il-31 to treat airway hyper-responsiveness and asthma: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proimflammatory cytokines and include administration of the IL-31 agonsit during sensitization or challenge resulting in the asthma, airway hyper-responsiveness... Agent: Zymogenetics, Inc. Intellectual Property Department

20080260688 - Novel inhibitors of glutaminyl cyclase: e

20080260689 - Peptides for active anti-cytokine immunization: Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angströms from an atom of the receptor corresponding to said... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080260687 - Specific binding agents for kshv vil-6 that neutralize a biological activity: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds... Agent: Klarquist Sparkman, LLP

20080260690 - Interferon in influenza: The use of an interferon (IFN) for the manufacture of a medicament for treatment and/or prevention of influenza, preferably avian influenza, is described in the present invention.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080260691 - Prodrugs of ribavirin with improved hepatic delivery: The present invention relates ribavirin delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to ribavarin and methods for administering conjugated ribavirin compositions.... Agent: Darby & Darby P.C.

20080260692 - Spirulin composition rich in active principles, method for obtaining same and use thereof: The invention relates to a spirulina combination composed of at least two distinct strain types from the genus Arthrospira, particularly Arthrospira LONAR and Arthrospira PARACAS whose phycocyanin content is between 13 and 30%, a method for obtaining such a combination, a composition containing this combination, and its use as a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080260693 - Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (lcmv): The present invention provides novel pseudotyped retroviral vectors that can transduce human and other cells. Vectors are provided that are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks expressing novel envelope glycoproteins. The present invention further relates to compositions for gene therapy.... Agent: Viksnins Harris & Padys Pllp

20080260707 - Isolated homozygous stem cells, differentiated cells derived therefrom and materials and methods for making and using same: The present invention discloses and describes pluripotent homozygous stem (HS) cells, and methods and materials for making same. The present invention also provides methods for differentiation of HS cells into progenitor (multipotent) cells or other desired cells, groups of cells or tissues. Further, the applications of the HS cells disclosed... Agent: Patton Boggs LLP

20080260705 - Preventing arrhythmias associated with cell transplantation: Skeletal myoblasts are an attractive cell type for transplantation since they are autologous and resistant to ischemia. However, clinical trials of myoblasts transplantation in heart failure have been plagued by ventricular tachy-arrhythmias and sudden cardiac death. The pathogenesis of these arrhythmias is poorly understood, but may be related to the... Agent: Banner & Witcoff, Ltd.

20080260706 - Transient transfection with rna: A method of mRNA production for use in transfection is provided, that involves in vitro transcription of PCR generated templates with specially designed primers, followed by polyA addition, to produce a construct containing 3′ and 5′ untranslated sequence (“UTR”), a 5′ cap and/or Internal Ribosome Entry Site (IRES), the gene... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080260694 - Multipotential expanded mesenchymal precursor cell progeny (memp) and uses thereof: The invention relates to multipotential expanded mesenchymal precursor progeny (MEMP's), characterised by the early developmental markers STRO-1bri and ALP. The present invention also relates to methods for producing MEMP's and to uses of MEMP's for therapeutic applications.... Agent: Cooper & Dunham, LLP

20080260695 - Composition for prevention and/or treatment of cancer: The invention relates to a composition for use in the prevention and treatment of cancer. The composition includes fermented soy extract, oligomeric proanthocyanidin, epigallocatiechin gallate, spirulina, curcumin and Antrodia camphorata. The composition of the invention effectively prevents the growth of cancer cells, especially colorectal cancer, ovarian cancer, breast cancer, cervical... Agent: Birch Stewart Kolasch & Birch

20080260696 - Method for decreasing inflammation and oxidative stress in mammals: The present invention is directed to a method for decreasing inflammation and oxidative stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to decrease a level of an oxidized glutathione and/or increase the... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080260708 - Methods and related systems and formulations to normalize and improve human body chemistry and healing ability: Methods, systems and formulations for normalizing and improving human body chemistry and the body's natural ability to heal itself. In one embodiment a system including effective amounts of a digestive enzyme, soluble and insoluble fiber, laxative, probiotics, vitamin C, potassium, protease enzymes, lipase, lysine, taurine, proline, choline, inositol, inositol hexaphosphate,... Agent: Greenberg Traurig LLP (la)

20080260709 - Cholesterol-lowering agents, secondary bile acid production inhibitors and foods and drinks: Secondary bile acid production inhibitors and cholesterol-lowering agents containing a yeast as the active ingredient.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260697 - Bacterial management in animal holding systems: The present invention is directed to method for reducing a population of a target pathogen in an animal or within a feedlot. The method involves administering one or more than one controlled release bacteriophage strain or phage component, or both, to the animal, so that the one, or more than... Agent: Brinks, Hofer, Gilson & Lione

20080260698 - Chimeric sindbis-western equine encephalitis virus and uses thereof: The present invention discloses a chimeric alphavirus comprising a Sindbis virus cDNA fragment, an Eastern equine encephalitis virus cDNA fragment, a Western equine encephalitis virus cDNA fragment or a combination thereof. The present also discloses the use of this chimeric alphavirus as vaccines and in serological and diagnostic assays.... Agent: Benjamin Aaron Adler Adler & Associates

20080260699 - Adminstration of intact mammalian cells to the brain by the intranasal route: The present invention provides an intranasal method for delivery of intact mammalian cells to the brain for treatment of neurological deficits. This approach applies an intranasal instillation to directly administer cells to the brain, and is useful as therapy for patients with neurological deficit or those who may benefit from... Agent: Richard Aron Osman

20080260701 - Anti-angiogenic cellular agent for cancer therapy: The invention provides cytokine induced killer (CIK) cell populations and methods of using CIK cells to treat cellular proliferative disorders. CIK cells generated in vitro include both bulk cultures and clones. Individual CIK cell clones display distinct but overlapping lytic specificities for tumor cells and endothelial cells in vitro. When... Agent: Beyer Weaver LLP

20080260704 - Combination treatment of cardiovascular disease: Disclosed are methods, compositions of matter and cells for treatment of cardiovascular disease through concurrent inhibition of oxidative stress while administration of a cell therapy. The invention also concerts the modulation of oxidative stress for preferential induction of differentiation while concurrently inhibiting inflammatory processes that decrease efficacy of cellular therapy.... Agent: Baumgartner Patent Law

20080260700 - Generation of pancreatic endocrine cells from primary duct cell cultures and methods of use for treatment of diabetes: The invention is directed to spontaneously immortalized pancreatic duct cells and methods for generating pancreatic endocrine cells from spontaneously immortalized pancreatic duct cells that express the transcription factors Pdx1 and FoxO1. The invention also provides for methods for treating beta cell failure, the method comprising administering to a subject an... Agent: Wilmerhale/columbia University

20080260703 - Treatment of insulin resistance and diabetes: Disclosed are methods, compositions, and cells useful for increasing insulin sensitivity, as well as lack of insulin production in a host in need thereof. One aspect of the invention discloses methods of increasing skeletal muscle perfusion through administration of cells capable of directly and/or indirectly stimulatory of angiogenesis and/or vascular... Agent: Baumgartner Patent Law

20080260702 - Treatment of retinopathies using gfra3 agonists: The present invention relates to the use of GFRα3 agonists for the treatment of disorders of the retina. A preferred GFRα3 agonist is Neublastin. Neublastin may be administered to the eye using protein formulations, in vivo or ex vivo gene therapy, or implantation of encapsulated cells delivering Neublastin locally to... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080260710 - Method for suppressing surgical site infection and column to be used for the method: An object of the present invention is to provide a method for suppressing surgical site infections (SSI) that have occurred at extremely high incidence rates at the time of surgical operations and particularly surgical operations on digestive system organs, and to provide a column to be used for the method.... Agent: Greenblum & Bernstein, P.L.C

20080260711 - Detoxifizyme with activity of transforming aflatoxin and the gene encodes thereof: The present invention relates to a detoxifizyme with the activity of transforming aflatoxin and the gene encodes thereof. Inventors firstly isolate and purify a novel protein, named aflatoxin-detoxifizyme (ADTZ), which has the activity of transforming aflatoxin. The primes specify to the ADTZ gene are obtained through purification and sequencing. The... Agent: Myers Dawes Andras & Sherman, LLP

20080260712 - Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability: A method of improving the resistance of collagenous tissue to mechanical degradation in accordance with the present invention comprises the step of contacting at least a portion of a collagenous tissue with an effective amount of a crosslinking reagent. Methods and devices for enhancing the body's own efforts to stabilize... Agent: Robert Berliner Berliner & Associates

20080260714 - Fibrin compositions containing strontium compounds: A composition for use in bone healing and bone regeneration in the form of a viscoelastic hydrogel gel or liquid formulation comprising fibrinogen, thrombin and an inorganic component comprising a strontium (Sr) containing compound and/or possibly another metal such as a calcium containing compound. The strontium containing compound can be... Agent: Howrey LLP - Dc

20080260713 - Neukinase, a downstream protein of neuregulin: The present invention relates to neukinase, a downstream protein kinase in the neuregulin signaling pathway. In certain aspects, the present invention provides isolated neukinase-encoding nucleic acids, neukinase polypeptides, oligonucleotides that hybridize to neukinase nucleic acids, and expression vectors containing neukinase-encoding sequences. The present invention further provides isolated host cells, antibodies,... Agent: Jones Day

20080260715 - Precursor n-acetylgalactosamine-4 sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme: The present invention provides a highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase and biologically active mutants, fragments and analogs thereof as well as pharmaceutical formulations comprising highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase. The invention also provides methods for treating diseases caused all or in part by deficiencies in human N-acetylgalactosamine-4-sulfatase including... Agent: Marshall, Gerstein & Borun LLP

20080260716 - Method and composition for high level disinfection employing quaternary ammonium compounds: Methods and compositions for high level disinfection (as herein defined) of a surface. Methods include treating the surface with a composition including a quaternary ammonium compound in a concentration which exceeds 1% w/w and the temperature of treatment is in the range of from 30° C. to 80° C. A... Agent: Edwards Angell Palmer & Dodge LLP

20080260724 - Drug induced exposure of the fungal pro-inflammatory molecule beta-glucan: Methods and reagents for screening for anti-microbial agents are provided. Diagnostic tools for assessing treatment of fungal infections are provided. Antimicrobial substances including substances useful for the treatment of fungal infections are provided. In some embodiments, the substances have antigen unmasking activity. In some embodiments the substances have fungicidal activity... Agent: Proskauer Rose LLP

20080260719 - Edg: modulators of lymphocyte activation and migration: The present invention relates to regulation of lymphocyte activation and migration. More particularly, the present invention is directed to nucleic acids encoding EDG family GPCR proteins, e.g., EDG-1, 2, 3, 4, 5, 6, 7, or 8, which are involved in modulation of lymphocyte activation and migration. The invention further relates... Agent: Klarquist Sparkman, LLP

20080260722 - Method for high efficiency survival/proliferation of human embyonic stem cells and human embryo survival in culture: The present invention provides a role for neurotrophins in hES cell survival and important new insights into the molecular mechanisms controlling the growth of these cells. Although previous studies identified growth factors that affect self-renewal of hES cells, the novelty of the present invention is the identification of factors that... Agent: Edwards Angell Palmer & Dodge LLP

20080260723 - Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor: One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one... Agent: Law Office Of John K. Pike, PLLC

20080260717 - Methods for reducing seizure-induced neuronal damage: This invention provides a method for treating a subject either during or soon after a seizure, in order to reduce the extent of neuronal damage in the subject resulting from the seizure comprising administering to the subject, either during or soon after the seizure, a therapeutically effective amount of an... Agent: Cooper & Dunham, LLP

20080260721 - Nucleic acids encoding a mammalian raptor polypeptide and uses therefor: The present invention relates to isolated raptor nucleic acid molecules of mammalian origin (e.g., human) and complements, portions and variants thereof. Another aspect of the invention are isolated raptor polypeptides of mammalian origin and portions thereof, and antibodies or antigen binding fragments thereof that specifically bind a raptor polypeptide. The... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080260726 - Organic compounds: A method of identifying a substance suitable for use in inhibiting mucus hypersecretion that modulates the activity of a human cathepsin C gene or its gene product. The method involves combining a candidate substance with the human cathepsin C gene or its gene product and measuring the effect of the... Agent: Novartis Institutes For Biomedical Research, Inc.

20080260718 - Phospholipase c gamma modulation and uses thereof for management of pain and nociception: The present invention provides methods of preventing and treating pain, by modulating, e.g. inhibiting, the activity, function and/or expression of a PLCγ in a subject. The invention further relates to methods of identifying agents capable of modulating the activity and/or expression of a PLCγ, or capable of modulating binding of... Agent: Ladas & Parry LLP

20080260720 - Systems and methods for inhibiting metastasis: The present invention relates to compositions and methods for cancer therapeutics. In particular, the present invention provides compositions and methods for inhibiting cancer metastasis by inhibiting G12 and G13 activity.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080260725 - Tag and target delivery system: A system for targeting dividing cells and delivering therapeutic agents to the targeted cells using a Tag nanoparticle. Each Tag nanoparticle comprises a nucleotide encoding a Tag, which is expressed only in dividing cells. The system optionally utilizes a microparticle to deliver Tag nanoparticles to cells. Therapeutic nanoparticles comprising therapeutic... Agent: Ratnerprestia

20080260732 - Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis: The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.... Agent: Howrey LLP-ca

20080260734 - Compositions and methods for characterizing, regulating, diagnosing, and treating cancer: The present invention relates to compositions and methods for characterizing, regulating, diagnosing, and treating cancer. For example, the present invention provides compositions and methods for inhibiting tumorigenesis of certain classes of cancer cells, including breast cancer cells and preventing metastasis. The present invention also provides systems and methods for identifying... Agent: Casimir Jones, S.c.

20080260733 - Humanized collagen antibodies and related methods: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic... Agent: Wilson Sonsini Goodrich & Rosati

20080260729 - Method of treating cancer comprising a vegf-b antgonist: The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their... Agent: Scully Scott Murphy & Presser, PC

20080260727 - Modulation of nkg2d: The present invention relates to methods and compositions for treating or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells and/or NK cells, by modulating NKG2D.... Agent: Medlen & Carroll, LLP

20080260731 - Optimized antibodies that target cd19: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20080260735 - Transfer request (37 cfr 1.821(e)) humanised antibodies to the epidermal growth factor receptor: The present invention provides a humanised form of the antibody 340 obtainable from the cell line deposited with the ECACC under accession number 97021428. Such antibodies have been found to have an increased ability to kill cells compared to the murine antibody 340. Also provided are nucleic acids encoding such... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080260730 - Treatment of crohn's disease or psoriasis using anti-interferon gamma antibodies: The present invention provides a method of treating autoimmune diseases. In particular, it provides a method for the treatment of Crohn's disease or psoriasis comprising administering to a subject in need thereof a therapeutically effective amount of an antibody against interferon γ.... Agent: Townsend And Townsend And Crew LLP

20080260728 - Treatment of severe multiple sclerosis: Methods of treating multiple sclerosis are disclosed.... Agent: Fish & Richardson

20080260737 - Combination of blys and/or april inhibition and immunnosuppressants for treatment of autoimmune disease: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment... Agent: Zymogenetics, Inc. Intellectual Property Department

20080260736 - Methods and compositions to regulate iron metabolism: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in... Agent: Clark & Elbing LLP

20080260738 - Single chain fc, methods of making and methods of treatment: The present invention relates generally to scFc molecules. The scFc molecules comprise at least two Fc regions and at least one linker, and can be produced in a variety of single chain configurations. The scFc molecules can further comprise at least one binding entity and/or at least one functional molecule.... Agent: Zymogenetics, Inc. Intellectual Property Department

20080260740 - Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer: Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage... Agent: Pdl Biopharma, Inc. Attn: Legal Department

20080260739 - Use of anti-mortalin 2 antibody and functional nucleic acid for cancer therapies: The present invention relates to cancer therapies using an antibody that binds to mortalin 2 and a functional nucleic acid. Mortalin expression was found to be upregulated in immortalized cells and tumor tissues. Immortalized human cells highly expressing mortalin showed anchorage-independent growth. When the K antibody, which is a specific... Agent: Sughrue Mion, PLLC

20080260746 - Erythropoietin polypeptides and uses thereof: The present invention relates to EPO polypeptides and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080260744 - G protein coupled receptors and uses thereof: The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists)... Agent: Seed Intellectual Property Law Group PLLC

20080260743 - Means and methods for detecting methylated dna: The present application relates to a nucleic acid molecule having a nucleotide sequence encoding a bifunctional polypeptide comprising the DNA-binding domain of a protein belonging to the family of Methyl-CpG binding proteins (MBDs) and the Fc portion of an antibody. In addition, vectors and host cells which comprise said nucleic... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080260747 - Methods and materials relating to cd84-like polypeptides and polynucleotides: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of... Agent: Nuvelo, Inc

20080260741 - Preventive and/or therapeutic agent for cancer: As the results of intensive studies aiming at providing a gene targeting a cancer cell or a cancer tissue, novel nucleotide sequences showing increased expression in a cancer cell or a cancer tissue compared with normal tissues are identified. As the results of the subsequent studies, genes showing increased expression... Agent: Edwards Angell Palmer & Dodge LLP

20080260742 - Preventives/remedies for cancer: The present invention provides preventives/remedies for cancer and so on. Specifically, an antibody against a protein comprising the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 17, SEQ ID NO: 25, SEQ ID NO: 38... Agent: Edwards Angell Palmer & Dodge LLP

20080260745 - Targeted identification of immunogenic peptides: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific... Agent: James Remenick Novak Druce & Quigg, LLP

20080260748 - Methods for damaging cells using effector function of anti-dsc2 antibody: The present invention is based on the discovery that the cytoxicity of anti-desmocollin 2 (DSC2) antibodies can be used for treating various cancers including lung, colon, pancreatic, prostate, breast, gastric or liver cancers. Specifically, the present invention provides antibodies against DSC2 that have effector function. Furthermore, the present invention provides... Agent: Townsend And Townsend And Crew, LLP

20080260749 - Novel tetrahydropyridothiophenes: e

20080260750 - Polynucleotides encoding acetylcholine-gated chloride channel subunits of caenorhabditis elegans: The invention relates to novel polynucleotides which encode novel polypeptides that are acetylcholine-gated chloride channel subunits and immunogenic or acetylcholine-binding fragments thereof. The novel polypeptides may be used for identifying compounds that modulate the acetylcholine-gated chloride channels, e.g. for use as pesticides and antiparasitic agents. Methods for identifying compounds that... Agent: Smart & Biggar P.o. Box 2999, Station D

20080260751 - Methods and compositions for the modulation of immune responses and autoimmune diseases: The present invention relates to a regulation of inflammation and immune responses. The present invention relates to a method of treating a condition comprising administering a pharmaceutically effective amount of an activator of RP105. The condition is typically associated with TLR-4 activation and cytokine production. Conditions addressed by the invention... Agent: Frost Brown Todd, LLC

20080260752 - Prevention and reduction of blood loss: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary... Agent: Lowrie, Lando & Anastasi, LLP

20080260754 - Compositions and methods for inhibition of the jak pathway: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.... Agent: Rigel Pharmaceuticals Inc.

20080260753 - Mouse models of crohn's disease and a method to develop specific therapeutics: Provided are compositions, transgenic animals and methods for screening and analyzing agents useful for treating inflammatory bowel diseases. Also provided are methods to treat inflammatory bowel disease, Crohn's disease and Blau syndrome.... Agent: Buchanan, Ingersoll & Rooney LLP

20080260756 - Peptide inhibitors of iaspp: The invention relates to a polypeptide or part thereof which inhibits the apoptotic activity of the tumor suppressor protein p53, and includes screening methods to identify agents which interfere with the activity of the polypeptide.... Agent: Marshall, Gerstein & Borun LLP

20080260755 - Proteolytically cleavable fusion proteins with high molar specific activity: The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080260757 - Bispecific fusion antibodies with enhanced serum half-life: Drug compositions, fusions and conjugates are provided. The drug fusions and conjugates contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The drug compositions, fusions and conjugates have a longer in vivo half-life in comparison with the... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080260758 - Universal gm-csf expressing bystander human k562 cell line: The present invention provides a universal immunomodulatory cytokine-expressing bystander cell line, a composition comprising such a cell line and a cancer antigen, a method of making such a cell line, and a method of using such a composition.... Agent: Barnes & Thornburg LLP

20080260761 - Compositions, splice variants and methods relating to cancer specific genes and proteins: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of... Agent: Licata & Tyrrell P.C.

20080260762 - Hla binding motifs and peptides and their uses: The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080260759 - Novel mite allergen: A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or... Agent: Greenblum & Bernstein, P.L.C

20080260760 - Prostate-specific antigen-derived mhc class h-restricted peptides and their use in vaccines to treat or prevent prostate cancer: The present invention relates to immunogenic peptides derived from human prostate cancer antigen (PSA-derived peptides) and their use as vaccines to treat or prevent prostate cancer. The invention is also related to dendritic cells from a patient having prostate cancer, which dendritic cells have been exposed to one or more... Agent: Evans & Molinelli, PLLC

20080260766 - Epitopes, combined epitopes, use of epitopes or their combination, composition, uses of the composition, anti-hiv-1 prophylactic vaccines, therapeutic vaccines, method for the identification of epitopes and methods for treatment and prevention: e

20080260763 - High throughput proteomics: Methods to obtain expression systems and proteins in a high-throughput protocol by utilizing mixtures of cells cultured from those transformed with a desired nucleotide sequence permit rapid production of protein for use in arrays to assess activity. In one embodiment, the proteins (or peptides) in the array are assessed for... Agent: Fish & Associates, PC Robert D. Fish

20080260765 - Hpv dna vaccines and methods of use thereof: Human papillomavirus (HPV) infection is the etiological factor for cervical cancer. Provided are HPV vaccines that generate a humoral immune response to prevent new infection, as well as cell-mediated immunotherapy to eliminate established infection or HPV-related disease. HPV vaccines include nucleic acid sequences encoding HPV16 early proteins E6 and E7.... Agent: Foley Hoag, LLP (w/jhv)

20080260764 - Replikin peptides and uses thereof: The present invention provides isolated influenza peptides and nucleic acid sequences and methods of identifying said influenza peptides and nucleic acid sequences having a pattern of substitution of amino acids or nucleic acids in highly conserved Replikin and Replikin Scaffold sequences that is predictive of rapid replication and virulence. Methods... Agent: Kenyon & Kenyon LLP

20080260767 - Novel protein which can be used, in particular, for the in vitro isolation and prevention of legionella pneumophila infections: The invention relates to novel polynucleotides, including SEQ ID NO: 1 or parts or variants of the sequence, novel polypeptides encoded by the polynucleotides, expression vectors including the polynucleotides and host cells including the expression vectors. The polynucleotides and polypeptides can be used in the field of in vitro diagnosis... Agent: Young & Thompson

20080260768 - Streptococcus pneumoniae proteins and nucleic acid molecules: Protein antigens from Streptococcus pneumoniae are disclosed, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.... Agent: Hunton & Williams LLP Intellectual Property Department

20080260769 - Polypeptides for oligomeric assembly of antigens: A system for expressing antigenic polypeptides in oligomeric form fuses the antigenic polypeptide to an oligomerisation polypeptide such that the oligomerisation polypeptide can interact with other oligomerisation polypeptides and bring multiple copies of the antigenic polypeptide into close proximity in the form of an oligomer. Expressing the polypeptides in oligomeric... Agent: Novartis Vaccines And Diagnostics Inc.

20080260770 - Use of tellurium compounds as adjuvants: Methods for enhancing the immune response of a subject to an immunoeffector, and methods of enhancing interleukin-12 production, which are effected by administering an amount of the immunoeffector and an effective adjuvanting amount of a tellurium-containing compound are provided. The enhanced immune response may be a cell-mediated or a humoral... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20080260772 - Extract from agaricus blazei murill capable of suppressing breast cancer: A food material capable of suppressing the genesis of breast cancer or proliferation of terminal breast cancer. An extract of Agaricus Blazei Murill comprising an ingredient capable of suppressing the genesis of breast cancer or proliferation of terminal breast cancer is provided. This ingredient can be a chromatographic main elution... Agent: Perkins Coie LLP

20080260771 - Prostate disorder(s) phyto-nutraceutical synergistic composition: A Phyto-nutraceutical composition for the prevention and treatment of prostate disorders is provided. A specific combination of extracts of plants and nutraceuticals is provided, based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization. Such combinations have synergistic effects, with minimal side effect.... Agent: Jose Olalde Rangel

20080260774 - Alpha-galactosyl ceramide analogs and their use as immunotherapies: wherein, n is 0 to 25; X is selected from O and S; R1 is selected from H, CH3, and phenyl, where phenyl is optionally substituted with H, OH, OCH3, F, CF3, phenyl, phenyl-F, C1-C6 alkyl, or C2-C6 branched alkyl; R2 is selected from OH and H; R3 is selected... Agent: Greenberg Traurig LLP (la)

20080260773 - Saccharide conjugate vaccines: The invention provides compositions comprising a combination of two or more monovalent conjugates, each of said two or more monovalent conjugates comprising a carrier protein comprising T cell epitopes from two or more pathogens conjugated to saccharide antigen. The invention also provides a multivalent conjugate comprising two or more antigenically... Agent: Novartis Vaccines And Diagnostics Inc.

20080260775 - New live virus vaccines: The present invention provides novel self-replicating and self-propagating chimeric viral vectors and chimeric virus particles comprising a modified genome of a carrier RNA virus packaged within structural proteins of a second virus. Also provided are pharmaceutical formulations comprising the chimeric viral vectors and virus particles and methods of inducing an... Agent: Myers Bigel Sibley & Sajovec

20080260776 - Preparation of salmonella broad-spectrum vaccines: The present invention relates to a pharmaceutical composition providing protective unity against a broad spectrum of Salmonella enterica serovars.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080260777 - Composition and method for controlling intestinal pathogenic organisms: An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes seven field strains of E. coli, Pseudomona aeruginosa, Aerobacter aerogenes, Salmonella enteritidis, Salmonella typhimurium, Salmonella agona, and Salmonella Kentucky. The antigen, composition can be used alone or in combination... Agent: Amin Hallihan, LLC

20080260778 - Method of vaccination against testicular bvdv infection: The methods of the invention relate to methods for preventing testicular infection by bovine viral diarrhea virus by immunizing susceptible male animals against infection.... Agent: Pharmacia & Upjohn

20080260779 - Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080260780 - Materials and methods relating to improved vaccination strategies: The invention provides novel vaccination strategies based on a prime-boost vaccination regiment. The inventors have determined improved ways of boosting an immune response in a patient previously primed or exposed to a plurality of epitopes. The improved method requires the epitopes in the boosting phase to be administered individually, i.e.... Agent: Foley And Lardner LLP Suite 500

20080260781 - Proteosome influenza vaccine: Improved forms of vaccines which comprise proteosomes and protein antigens are described. Vaccines which contain influenza HA as the antigen are used for illustration as to demonstrate efficacy. Improvements in the preparation of the vaccines themselves and the proteosome component are also included.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080260782 - Mycobacterium avium subspecies paratuberculosis vaccines and methods of using the same: The invention relates to vaccine compositions composed of at least one Mycobacterium avium subspecies paratuberculosis (MAP) antigen, or attenuated or killed MAP for use in methods of immunizing a human against a MAP infection, preventing or treating a MAP infection, and preventing a human disease associated with a MAP infection.... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20080260783 - Composition and method for controlling intestinal pathogenic organisms: An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes naturally-occurring wild Salmonella enterica subspecies in O-serogroups B, C2 and D. Subspecies in O-serogroup B can include Salmonella typhimurium and/or Salmonella agona. Subspecies in O-serogroup C2 can include Salmonella... Agent: Amin Hallihan, LLC

20080260784 - Compositions and methods for modulating an immune response: The present invention provides a composition for suppressing an inflammatory immune response comprising the excretory/secretory (ES) component of Fasciola hepatica or a fraction thereof. The composition has particular utility in the treatment or prophylaxis of T cell mediated inflammatory immune responses, and in particular autoimmune disease. The invention further extends... Agent: Marshall, Gerstein & Borun LLP

20080260785 - Paroxetine compositions: The invention relates to pharmaceutical compositions having polymers that release paroxetine in a controlled manner for a prolonged or sustained period of time. An embodiment of the invention provides enhanced bioavailability controlled release pharmaceutical compositions comprising paroxetine or its pharmaceutically acceptable salts, which enables a reduction in its orally administered... Agent: Dr. Reddy's Laboratories, Inc.

20080260786 - Process for making encapsulated particles: Method for preparing an active-containing starch matrix and the free flowing, dry powder that results from such a process. The active ingredients can be released (deposited) onto a surface by normal triggering mechanisms, which include the action of a liquid or by friction or rubbing. The fixative systems described herein... Agent: National Starch And Chemical Company

20080260787 - Use of collagen in combination with oxygen- and ozone-releasing perfluorocarbons for the preparation of a medicament for the treatment of skin lesions: A medicament and a medication for the treatment of skin lesions are disclosed, which comprise collagen and an oxygen-carrying and releasing fluorinated hydrocarbon and, optionally and preferably additionally, ozone. Particularly, the invention relates to a kit for the topical administration of such a medicament on the damaged skin, as well... Agent: Pearne & Gordon LLP

20080260788 - Skin cleaning composition: The present invention describes a skin cleaning and disinfecting composition comprising an active component, wherein the active component comprises at least one alcohol, at least one halogen. The present invention also describes corresponding anti-bacterial, anti-viral and anti-fungal compositions, as well as a method of manufacturing same.... Agent: Greenberg Traurig LLP (la)

20080260789 - Insecticidal polypeptides and methods of use thereof: A family of insecticidal polypeptides expressed in the venom gland of spiders of the genera Atrax and Hadronyche have been described. Also included are polynucleotides and expression vectors encoding the polypeptides and insect viruses and cells expressing the polypeptides. Transgenic plants and insects expressing the insecticidal polypeptides are also described.... Agent: Johathan P. O''brien Miller, Canfield, Paddock And Stone, P.L.C

20080260791 - Injectable capsaicin: The present invention provides compositions and methods for relieving pain at a site in a human or animal in need thereof by administering at a discrete site in a human or animal in need thereof a dose of capsaicin in an amount effective to denervate a discrete site without eliciting... Agent: Davidson, Davidson & Kappel, LLC

20080260792 - Method to use therapeutic microencapsulation of embedding parathyroid live cells with theracyte: A method to use a therapeutic microencapsulation of embedding parathyroid live cells with a TheraCyte comprises the steps of: (1) containing the parathyroid live cells in −179° C. liquid nitrogen and then unfrozen for preparing the therapeutic microencapsulation; (2) embedding at least 4×105 parathyroid live cells in the TheraCyte to... Agent: Nikolai & Mersereau, P.A.

20080260790 - Plasmid enhancement agent for high intensity focused ultrasound treatment and use thereof: The present invention discloses a plasmid enhancement agent for high intensity focused ultrasound (HIFU) treatment, which can increase acoustic energy deposition at the target location during HIFU treatment. The enhancement agent comprises a nanometer-sized biocompatible solid. The present invention also discloses another plasmid enhancement agent for HIFU treatment, wherein, the... Agent: The Webb Law Firm, P.C.

20080260793 - Porous gelatin material, gelatin structures, methods for preparation of the same and uses thereof: The present invention relates to a porous gelatin material in the form of spherical particles with a continuous pore structure and cast, three-dimensional, porous gelatin structures. The invention also comprises methods for preparation of the porous gelatin materials and structures. The method for preparing the porous gelatin material in the... Agent: Morgan Lewis & Bockius LLP

20080260798 - Aligned scaffolds for improved myocardial regeneration: The present invention relates to a biocompatible, three-dimensional scaffold useful to grow cells and to regenerate or repair tissue in predetermined orientations. The scaffold is particularly useful for regeneration and repair of cardiac tissue. The scaffold contains layers of alternating A-strips and S-strips, wherein the A-strips within each layer are... Agent: Fulbright & Jaworski L.L.P.

20080260799 - Bioactive implant and method of use: The invention relates to a method for producing bioactive implant surfaces consisting of metallic or ceramic materials, to be used for implants such as artificial joints or very small implants such as so-called stents. The invention also relates to implants produced according to this method and methods of using the... Agent: Foley & Lardner LLP

20080260794 - Collagen products and methods for producing collagen products: Medical implants and methods for forming a medical implant blends a dispersion of human collagen fibers and/or threads and optionally a volume between about 2 to about 15% of an alcohol and forms medical implants by removing a liquid component of the collagen dispersion. Medical implants formed include collagen films,... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080260797 - Methods of treating disease with nitric oxide (no)-releasing polymers and soluble no-releasing nitrosamines: The invention provides NO-releasing polymers and low molecular weight NO-releasing compounds which may be used to for the treatment of medical conditions associated with NO-deficiency. The NO-releasing polymers or the low molecular weight NO-releasing compounds may also be incorporated into medical devices. The invention further provides methods of controlled release... Agent: Michael Best & Friedrich LLP

20080260796 - Reduction of infection associated with medical device: Anti-infective articles capable of preventing infection associated with implantation of medical devices include low levels of anti-infective agents, may cover only a fraction of the portion of the medical device and be effective, or may rapidly elute anti-infective agent, without sustained elution, and still be effective.... Agent: Campbell Nelson Whipps, LLC

20080260795 - Strong reversible hydrogels: The present invention relates to improved hydrogel materials using water gellants that are comprised of polymer backbones P to which hydrogen bonding 4H-units are covalently attached via a hydrophobic linker L. Optionally, the hydrogel contains additional ingredients or additives. These new reversible hydrogels can easily be fine-tuned in their mechanical... Agent: Foley And Lardner LLP Suite 500

20080260800 - Extracellular matrix cancer vaccine adjuvant: Compositions suitable for use as adjuvants in the preparation of vaccines, particularly those vaccines useful in the treatment of cancer, are provided. Methods for inhibiting tumor growth in an animal are also disclosed. Methods for immunizing an animal against cancer, such as prostate cancer, are also described. The adjuvants described... Agent: Bell, Boyd, & Lloyd LLP

20080260802 - Biocompatible hydrogels made with small molecule precursors: Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic functional groups capable of reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable, or not, are provided,... Agent: Dardi & Associates, PLLC

20080260801 - Composite material, especially for medical use, and method for producing the material: o

20080260803 - Sustained release intraocular inplants containing tyrosine kinase inhibitors and related methods: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix... Agent: Stephen Donovan

20080260804 - Medical devices having antimicrobial coatings thereon: The present invention provides a medical device, preferably a contact lens, which comprises an antimicrobial coating including at least one layer of polyquat of formula (I) or (II). The antimicrobial coating on the medical device of the invention has a high antimicrobial efficacy against microorganisms including Gram-positive and Gram-negative bacterial,... Agent: Ciba Vision Corporation Patent Department

20080260805 - Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom: The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to... Agent: Hoffmann & Baron, LLP

20080260808 - Device for smoothing wrinkles on human skin: Device for smoothing wrinkles on human skin and for enabling skin sections between successive wrinkles to achieve prolonged contact with cosmetic and/or pharmaceutical substances carried by said device.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260806 - Personal hygiene compositions and methods: A personal hygiene composition, which may be coated on a towelette, comprises an astringent, a humectant, and a botanical extract. In some embodiments, the botanical extract can be selected from the group consisting of Hydrastis Canadensis, Tabebuia Impetiginosa, Hymenaea Courbaril, Ptychopetalum Olacoides, Juniperus Brasiliensis, Hamamelis Virginiana, and mixtures thereof. The... Agent: Harness, Dickey & Pierce, P.L.C

20080260809 - Polyethylene oxide-based films and drug delivery systems made therefrom: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component,... Agent: Hoffmann & Baron, LLP

20080260807 - Water-soluble films comprising nicotine: A water-soluble film comprising nicotine, wherein said nicotine may be any pharmacologically effective form of nicotine present at one or more locations of the film defined by the application of a nicotine-containing fluid to at least one surface of a preformed water-soluble film.... Agent: Mcdermott Will & Emery LLP

20080260810 - Hemostat: The present invention is directed towards a hemostat comprising an absorbable foam, an absorbable woven or knitted fabric, thrombin and/or fibrinogen.... Agent: Philip S. Johnson Johnson & Johnson

20080260811 - Transdermal delivery systems: Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form... Agent: Thomas P. Mccracken Durect Corporation

20080260812 - Therapeutic medicine containing monoclonal antibody against folate receptor beta (fr-beta): An objective of the present invention is to provide a therapeutic agent for treating rheumatoid arthritis, juvenile rheumatoid arthritis, macrophage activation syndrome, septicemia, and FR-β expressing leukemia, which induces apoptosis in activated macrophages and folate receptor beta (FR-β) expressing leukemia cells to specifically destroy these cells. An FR-β monoclonal antibody... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260813 - Pharmaceutical composition of topiramate: The invention is directed to a pharmaceutical composition of topiramate, an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage formulation of topiramate intended primarily for use by pediatric patients, or for patients who have difficulty swallowing tablets. Processes for preparing the pharmaceutical... Agent: Philip S. Johnson Johnson & Johnson

20080260814 - Injection moulding process for neutral and acid-group-containing (meth)acrylate copolymers: Processes for producing moldings by injection moulding, include melting a mixture made from a (meth)acrylate copolymer and a release agent, devolatilizing the mixture, injecting the molten and devolatilized mixture into a mold cavity of an injection mold, cooling the molten mixture, and removing the resultant molding from the mold.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260815 - Multiparticulates: Extrusion of a mix containing a pharmaceutically active agent can be achieved using a plasticising excipient in an amount sufficient to act as plasticiser and also act as lubricant, thereby avoiding the need for inclusion of a lubricant. The invention provides multiparticulates with controlled release properties, substantially free of lubricant.... Agent: Duane Morris LLP - Ny Patent Department

20080260816 - Particulate lipid pharmaceutical composition: A particulate lipid pharmaceutical composition comprises a particulate solid non-lipid carrier and an oil-in-water emulsion on the carrier. The emulsion comprises a dissolved or dispersed pharmacologically active agent. The oil-in-water emulsion is released from the carrier on contact with an aqueous media to form an oil-in-water emulsion in the media.... Agent: Nixon & Vanderhye, PC

20080260817 - Compositions for the treatment of inflammation and pain using a combination of a cox-2 selective inhibitor and a ltb4 receptor antagonist: The present invention provides a therapeutic composition comprising a COX-2 selective inhibitor or a prodrug thereof and an LTB4 receptor antagonist. A method is provided for the use of such composition in the treatment, prevention, or inhibition of inflammation, an inflammation-related disorder, pain, or a pain-related disorder.... Agent: Pharmacia Corporation Global Patent Department

20080260818 - Controlled absorption of statins in the intestine: The present invention